Nasdaq

Cytokinetics Announces Additional Results From GALACTIC-HF Presented at the European Society of Cardiology Heart Failure 2021

Further Analyses of GALACTIC-HF Supplement Previously Announced Data Regarding Increased Treatment Effect of Omecamtiv Mecarbil in Patients with More Severe Heart Failure SOUTH SAN FRANCISCO, Calif., ...
Nasdaq

Cytokinetics Announces GALACTIC-HF Accepted for Presentation In Late Breaking Clinical Trial Session At American Heart Association Scientific Sessions

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through ...
Business Insider

Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis

GALACTIC-HF, one of the largest Phase 3 global cardiovascular outcomes studies in heart failure ever conducted, has now completed enrollment of more than 8,200 patients in 35 countries who were either ...
The American Journal of Managed Care

Omecamtiv Mecarbil Shown to Improve Cardiac Function, Clinical Outcomes in GALACTIC-HF

Findings from the GALACTIC-HF trial presented at AHA Scientific Sessions 2020 showed that patients with heart failure (HF) with reduced ejection fraction who took omecamtiv mecarbil showed a ...
Healio

GALACTIC-HF: Omecamtiv mecarbil effective in patients with severe HF

Please provide your email address to receive an email when new articles are posted on . In a post hoc analysis of the GALACTIC-HF trial, omecamtiv mecarbil reduced the primary endpoint of time to ...
TCTMD

Modest Gains With Omecamtiv Mecarbil in Chronic HFrEF: GALACTIC-HF

When added to standard therapies, omecamtiv mecarbil—a novel cardiac myosin activator, or myotrope—significantly reduces the combined risk of first heart failure events or CV death in patients with ...
Business Insider

Cytokinetics Announces Baseline Characteristics from GALACTIC-HF at ACC.20/WCC Virtual

SOUTH SAN FRANCISCO, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that patient baseline characteristics and demographics from GALACTIC-HF ...
Healio

GALACTIC-HF: Benefit of omecamtiv mecarbil strongest at lowest EF

Please provide your email address to receive an email when new articles are posted on . As Healio previously reported, in the main results of GALACTIC-HF, for patients with symptomatic chronic HF with ...
Pharmabiz

Amgen, Cytokinetics and Servier announce postive results from GALACTIC-HF phase 3 trial of omecamtiv mecarbil in patients with heart failure

Amgen, Cytokinetics and Servier announced topline results from GALACTIC-HF, a phase 3 pivotal clinical trial of omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF) ...
Medscape

No Survival Gain From Aggressive Vasodilator Strategy in Acute HF: GALACTIC

Early vasodilator therapy, even when aggressive, does little to improve survival or other clinical outcomes for patients hospitalized with acute heart failure (HF), suggests only the latest randomized ...
CNN

Correction: Cytokinetics Announces Baseline Characteristics from GALACTIC-HF at ACC.20/WCC Virtual

“Patients enrolled in GALACTIC-HF represent a heart failure population at risk for cardiovascular events despite being well-treated in accordance with international guidelines. The baseline patient ...